- Home
- SRFM vs CHRS Comparison
SRFM vs CHRS Comparison
Compare SRFM & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRFM
- CHRS
- Stock Information
- Founded
- SRFM 2011
- CHRS 2010
- Country
- SRFM United States
- CHRS United States
- Employees
- SRFM N/A
- CHRS N/A
- Industry
- SRFM Transportation Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SRFM Consumer Discretionary
- CHRS Health Care
- Exchange
- SRFM Nasdaq
- CHRS Nasdaq
- Market Cap
- SRFM 114.6M
- CHRS 102.0M
- IPO Year
- SRFM 2023
- CHRS 2014
- Fundamental
- Price
- SRFM $5.79
- CHRS $1.04
- Analyst Decision
- SRFM Buy
- CHRS Buy
- Analyst Count
- SRFM 4
- CHRS 3
- Target Price
- SRFM $5.56
- CHRS $4.68
- AVG Volume (30 Days)
- SRFM 12.2M
- CHRS 1.3M
- Earning Date
- SRFM 08-13-2025
- CHRS 08-07-2025
- Dividend Yield
- SRFM N/A
- CHRS N/A
- EPS Growth
- SRFM N/A
- CHRS N/A
- EPS
- SRFM N/A
- CHRS N/A
- Revenue
- SRFM $112,307,000.00
- CHRS $272,251,000.00
- Revenue This Year
- SRFM N/A
- CHRS N/A
- Revenue Next Year
- SRFM $54.32
- CHRS $99.43
- P/E Ratio
- SRFM N/A
- CHRS $2.44
- Revenue Growth
- SRFM 31.17
- CHRS 19.87
- 52 Week Low
- SRFM $0.90
- CHRS $0.66
- 52 Week High
- SRFM $9.91
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- SRFM 57.00
- CHRS 68.96
- Support Level
- SRFM $4.50
- CHRS $0.88
- Resistance Level
- SRFM $9.91
- CHRS $1.06
- Average True Range (ATR)
- SRFM 1.31
- CHRS 0.07
- MACD
- SRFM -0.16
- CHRS 0.02
- Stochastic Oscillator
- SRFM 23.84
- CHRS 93.38
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.